In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
News|Articles|January 6, 2026
Q1 2026: 5 FDA Decisions to Watch in the Realm of Oncology
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.
Advertisement
Advertisement
As Q1 begins, the oncology community is closely watching the FDA for several key regulatory decisions. With potential approvals spanning a range of therapeutic areas, the next few months could introduce new treatment options and reshape current standards of care.
Related to this article
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.
Advertisement
Advertisement